RNAlead
keyboard_backspaceBack to Home
Contact
Centre Pierre Potier, 1 place Pierre Potier
31100 Toulouse
France
CEO - CSO
About us
RNAlead was created to provide our cutting-edge proprietary RNA delivery technology platform in a customized end-to-end solution, including manufacturing tech-transfer and licensing solutions.
Designed to be more efficient, more accessible, and clinic-ready, FlashRNA® platform sets a new standard for safer, targeted RNA-based therapeutics.
Business offer
FlashRNA® is a RNA transfer tool, combining the external structure of a lentivirus associated with a specific RNA packaging system derived from bacteriophages.
This unique combination associates the efficient cell transfer capability of lentiviral vectors with the recruitment of multiple RNA molecules manufactured through a biological process. FlashRNA® thus offers unrivalled performance and safety for multiple RNA delivery, in vitro as well as in vivo.
FlashRNA® is ready for therapy as a drug product, thanks to a validated scale-up.
Activities
- Therapeutic Product
- Genetic Diseases
- Oncology
- Hematology
- Infectiology
- Immunology
- Ophthalmology
- Cell origin
- Cell Banking
- IPs
- MSC
- CD34 + HSC cells
- Target cell isolation
- Differentiated Cell
- Production Cell
- Cell modification
- Direct reprogramming
- Cell Activation
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- CMC/analytical quality assessment, quality control
- Cleaning
- Sterility
- Contaminants detection
- Bioproduction engineering
- Cell Expansion
- Cell factory
- Microcarrier-based culture
- Scale-Up
- Process optimization
- Non-GMP expansion
- GMP expansion
- Purification/Extraction
- Filtration / microfiltration / ultrafiltration
- Centrifugation
- Chromatography
- CGMP
- Formulation
- Conditioning
- Storage
- Target Identification
- Gene / protein discovery
- bioinformatics design
- Expression and pathway analysis of target
- quantification of target
- Gene Cloning
- Gene augmentation
- Gene inhibition
- KI / KO
- (Gene) engineering
- CRISPR interference
- TRAC gene editing
- Gene Delivery System
- Lentivirus
- Other Retrovirus
- CAR Construction
- T-cell activation/transduction
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- Antigen-protective immune-response profile
- Cell mediated immunity response
- T cell assays
- Research exploratory biomarkers
- efficiency vaccination
- Vaccine: antigen format platforms
- mRNA vaccine
- CMC
- GMP compliance
- Cell expansion
- Single use technology (SUS)
- Gene modification / Transduction
- Molecular biology
- Expression systems
- Formulation
- Formulation
- Vaccines Combination
- Lyophilization
- Vaccine delivery/Administration routes
- Route of Administration
- Intramuscular route
- intradermal route
- Nasal route
- Mucosal routes
- Other devices: specify
- Clinical trials
- Phase I
- Phase II (human challenge trials)
- Bioproduction GMP
- Vaccine platform type
- Virus-like particles (VLP) and nanoparticle-based carriers
- mRNA vaccine
- Other
- Pilot Batches scale
- Process development & optimization
- Scale-Up & Validation
- Manufacturing Volume
- Small volume (< 100 L) adjusted to phase I/II needs: specify volume
- USP (Scale-Up)
- DSP (Recovery)
- Regulatory Filing
- Regulatory Filing
- New Drug Application (IND)
- Investigational Medicinal Product (IMPT) for clinical investigations (EMA)
